ViroLogic Gets Molecular Cancer Test Platform With Aclara
This article was originally published in The Gray Sheet
Executive Summary
ViroLogic will leverage its established HIV resistance test infrastructure to commercialize Aclara's eTag molecular cancer assay platform under a $200 mil. definitive acquisition agreement, announced June 1